However, clinical benefit is associated with high tumor mutational load [27], high pretreatment levels of PD-L1 on tumor cells, and tumor-infiltrating immune cells [28,29,30], and high pretreatment levels of tumor-infiltrating lymphocytes [31]. Here, CD274 is linked to neoplasm.